纳米颗粒T细胞衔接器作为模块化癌症免疫治疗平台
研究开发了基于脂质体的纳米双特异性T细胞衔接器(nanoBiTE)及靶向多种癌症抗原的纳米多特异性T细胞衔接器(nanoMuTE),半衰期约60小时,支持每周一次给药。nanoMuTE在体外和体内对骨髓瘤细胞疗效优于nanoBiTE,且不引起单一抗原下调,可防止抗原缺失肿瘤逃逸。
要点
- nanoBiTE和nanoMuTE半衰期约60小时,可实现每周一次给药而非持续输注。
- 靶向多抗原的nanoMuTE在骨髓瘤中体外和体内疗效优于单抗原nanoBiTE。
- nanoMuTE不引起单一抗原下调,可防止抗原缺失克隆逃逸。
核心结论
- 纳米颗粒免疫衔接技术可解决现有T细胞免疫治疗半衰期短和单抗原靶向导致肿瘤逃逸的主要局限。
研究设计与样本
- 研究构建了脂质体装饰抗CD3单克隆抗体和抗癌症抗原单克隆抗体的nanoBiTE,以及偶联多种抗多种癌症抗原单克隆抗体的nanoMuTE,并进行了体外和体内评价。
主要发现
- nanoBiTE和nanoMuTE半衰期约60小时,在体外和体内维持疗效。
- nanoMuTE靶向多种癌症抗原,在体外和体内对骨髓瘤细胞的疗效优于靶向单一癌症抗原的nanoBiTE。
- 与nanoBiTE不同,nanoMuTE治疗未引起单一抗原下调或丢失,并防止了抗原缺失肿瘤逃逸的发生。
关键数值与推荐
- nanoBiTE和nanoMuTE半衰期约60小时,支持每周一次给药而非持续输注。
临床怎么用
- 纳米多特异性T细胞衔接器平台有望实现每周一次给药并减少抗原逃逸,但尚需临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell-based immunotherapy, such as CAR-T cells and bispecific T-cell engagers (BiTEs), has shown promising clinical outcomes in many cancers; however, these therapies have significant limitations, such as poor pharmacokinetics and the ability to target only one antigen on the cancer cells. In multiclonal diseases, these therapies confer the development of antigen-less clones, causing tumor escape and relapse. In this study, we developed nanoparticle-based bispecific T-cell engagers (nanoBiTEs), which are liposomes decorated with anti-CD3 monoclonal antibodies (mAbs) targeting T cells, and mAbs targeting the cancer antigen. We also developed a nanoparticle that targets multiple cancer antigens by conjugating multiple mAbs against multiple cancer antigens for T-cell engagement (nanoMuTEs). NanoBiTEs and nanoMuTEs have a long half-life of about 60 h, which enables once-a-week administration instead of continuous infusion, while maintaining efficacy in vitro and in vivo. NanoMuTEs targeting multiple cancer antigens showed greater efficacy in myeloma cells in vitro and in vivo, compared to nanoBiTEs targeting only one cancer antigen. Unlike nanoBiTEs, treatment with nanoMuTEs did not cause downregulation (or loss) of a single antigen, and prevented the development of antigen-less tumor escape. Our nanoparticle-based immuno-engaging technology provides a solution for the major limitations of current immunotherapy technologies.
引用
- Alhallak K, Sun J, Wasden K, et al. Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy. Leukemia. 2021. PMID: 33479469. doi:10.1038/s41375-021-01127-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。